Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finance Watch: Five IPOs Launch In Two Days; Three Remain In Positive Territory

Executive Summary

Public Company Edition: Trevi Therapeutics was the first out of the gate on 7 May, but four more biopharma firms went public in the US on 8 May, while just 13 IPOs launched between January and April. Also, new financings include debt for BMS, Bausch and Intercept.

Advertisement

Related Content

Intercept's OCA Data Bolster NASH Efficacy, But Pruritus Worries Worsen
Aerie Looks To Grow Its Two Glaucoma Products In Tandem
Finance Watch: Gossamer, Alector And Harpoon Launch First Biopharma IPOs Of 2019
Bristol Values Celgene's Hematology, Immunology Portfolio At $74bn, But Does It Price In Risk?
Merck KGAA/Pfizer's Bavencio Failure Casts More Shade On Immunotherapy For Ovarian Cancer
NextCure Hopes Its Novel Target Therapies Will Treat Patients Not Helped By PD-1/L1 Inhibition
Clovis In Pole Position To Be First PARP For Prostate Cancer
IPO Update: Returns Sag As Seven More Biopharmas Go Public In September
Good Prospects For Athenex/Almirall Following PhIII Actinic Keratosis Results
Milestone Pharmaceuticals Inc.

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC125205

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel